Patent intelligence · US
US 2019076525
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
Patent details — US 2019076525
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 14, 2019
- Expiration
- Mar 9, 2039
- Applicant
- GANYMED PHARMACEUTICALS GMBH [DE]
- CPC classes
- A61K 39/ 39 A I, A61K 39/ 395 A I, A61K 45/ 06 A I, A61K/39395
Quick answer
US 2019076525 (THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER) is held by GANYMED PHARMACEUTICALS GMBH [DE]. Status: granted. Granted Mar 14, 2019. Expires Mar 9, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GANYMED PHARMACEUTICALS GMBH [DE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 39 A I, A61K 39/ 395 A I, A61K 45/ 06 A I, A61K/39395, A61K/3939558, A61K/4506
More from GANYMED PHARMACEUTICALS GMBH [DE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022206771
Drug conjugates comprising antibodies against Claudin 18.2
granted -
EP 3791896
KOMBINATIONSTHERAPIE MIT ANTIKÖRPERN GEGEN CLAUDIN 18.2 ZUR BEHANDLUNG VON KREBS
granted -
LT 3254695
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
granted -
EP 3708579
CLAUDIN-6-SPEZIFISCHE IMMUNREZPTOREN UND T-ZELL-EPITOPE
granted -
HR P20200591
ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6)
granted -
US 2020199221
ANTIBODIES USEFUL IN CANCER DIAGNOSIS
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted
Frequently asked questions
What is US patent 2019076525?
US 2019076525 (THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER) is held by GANYMED PHARMACEUTICALS GMBH [DE]. Status: granted. Granted Mar 14, 2019. Expires Mar 9, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2019076525?
GANYMED PHARMACEUTICALS GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2019076525 expire?
Our index shows an expiration date of Mar 9, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.